LadRx Co. (OTCMKTS:CYTR – Get Rating) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 19,900 shares, a decline of 46.2% from the September 15th total of 37,000 shares. Based on an average trading volume of 103,700 shares, the short-interest ratio is presently 0.2 days.

LadRx Price Performance

The company has a fifty day moving average price of $0.10 and a 200-day moving average price of $0.13. The firm has a market capitalization of $4.14 million, a price-to-earnings ratio of -0.61 and a beta of 1.96. LadRx has a 1-year low of $0.05 and a 1-year high of $0.86.

LadRx (OTCMKTS:CYTR – Get Rating) last issued its earnings results on Thursday, August 11th. The biotechnology company reported ($0.02) EPS for the quarter.

LadRx Company Profile

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022.

Featured Stories

• Get a free copy of the StockNews.com research report on LadRx (CYTR)
• Constellation Brands Stock May Offer Safety in the Market Storm
• Domino's Pizza Rises To The Occasion In Q3
• Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
• O'Reilly & AutoZone Outperform The S&P: Is Either A Better Stock?
• Three Dividend Growers the Institutions Are Buying

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.